Immunome's NDA for Varegacestat Accepted by FDA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 13 hours ago
0mins
Source: Newsfilter
- FDA Acceptance of NDA: Immunome's New Drug Application for varegacestat has been accepted by the FDA with a target action date of April 28, 2027, marking a significant milestone in providing a new oral treatment option for adults with desmoid tumors.
- Significant Clinical Trial Results: The Phase 3 RINGSIDE trial demonstrated that varegacestat met its primary endpoint by achieving an 84% reduction in the risk of disease progression or death, establishing a strong foundation for its market potential.
- Good Safety Profile: Varegacestat was generally well tolerated in the trial, with common adverse events such as diarrhea (82%) and fatigue (44%), and most events were grade 1 or 2, indicating an acceptable safety profile that supports future marketing efforts.
- Broad Market Potential: Approximately 1,000 to 1,650 patients are diagnosed with desmoid tumors annually in the U.S., and Immunome plans to submit a Marketing Authorization Application to the European Medicines Agency by the end of 2026, indicating its intent to expand in the global market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMNM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMNM
Wall Street analysts forecast IMNM stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 24.390
Low
21.00
Averages
33.20
High
40.00
Current: 24.390
Low
21.00
Averages
33.20
High
40.00
About IMNM
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immunome's NDA for Varegacestat Accepted by FDA
- FDA Acceptance of NDA: Immunome's New Drug Application for varegacestat has been accepted by the FDA with a target action date of April 28, 2027, marking a significant milestone in providing a new oral treatment option for adults with desmoid tumors.
- Significant Clinical Trial Results: The Phase 3 RINGSIDE trial demonstrated that varegacestat met its primary endpoint by achieving an 84% reduction in the risk of disease progression or death, establishing a strong foundation for its market potential.
- Good Safety Profile: Varegacestat was generally well tolerated in the trial, with common adverse events such as diarrhea (82%) and fatigue (44%), and most events were grade 1 or 2, indicating an acceptable safety profile that supports future marketing efforts.
- Broad Market Potential: Approximately 1,000 to 1,650 patients are diagnosed with desmoid tumors annually in the U.S., and Immunome plans to submit a Marketing Authorization Application to the European Medicines Agency by the end of 2026, indicating its intent to expand in the global market.
See More
Immunome Receives FDA Acceptance for Varegacestat Application
- FDA Application Acceptance: Immunome announced that the U.S. FDA has accepted its marketing application for varegacestat, aimed at noncancerous soft tissue lesions, marking a significant advancement in the biotech sector.
- Clinical Trial Success: In the global Phase 3 RINGSIDE trial involving 156 patients, varegacestat achieved an 84% reduction in the risk of disease progression or death, demonstrating statistically significant clinical impact that could alter treatment paradigms.
- Secondary Goals Met: The RINGSIDE trial also met all key secondary endpoints, with an objective response rate of 56% in patients receiving varegacestat compared to just 9% in the placebo group, highlighting the drug's efficacy.
- Significant Market Potential: Approximately 1,000-1,650 Americans are diagnosed with desmoid tumors annually, requiring systemic treatment to prevent organ damage and pain, indicating a substantial market opportunity for this drug.
See More
Immunome Initiates Phase 1 Trial for IM-1617 ADC
- Trial Initiation: Immunome announced that the first patient has been dosed in the Phase 1 trial of IM-1617, an antibody-drug conjugate (ADC) aimed at assessing safety and preliminary anti-tumor activity, marking a significant advancement in targeted cancer therapies.
- Drug Mechanism: IM-1617 incorporates Immunome's proprietary topoisomerase I inhibitor HC74 and targets an undisclosed solid tumor receptor, with preclinical studies demonstrating impressive tumor regression across various models, indicating substantial clinical potential.
- Future Plans: Immunome plans to submit investigational new drug (IND) applications for IM-1340 and IM-1335 in mid and late 2026, respectively, reflecting the company's ongoing momentum and strategic focus in oncology drug development.
- Market Outlook: As IM-1617 progresses through clinical trials, Immunome anticipates strengthening its market position in targeted cancer therapies, providing innovative treatment options for patients and driving long-term growth for the company.
See More
Immunome Q1 Earnings Beat Expectations
- Earnings Surprise: Immunome reported a Q1 GAAP EPS of -$0.48, beating expectations by $0.09, indicating an improvement in financial performance that could bolster investor confidence.
- Strong Cash Position: As of March 31, 2026, Immunome's cash and cash equivalents totaled $582.7 million, which is expected to fund operations into 2028, ensuring continuity in research and operational activities.
- Optimistic Future Outlook: The company anticipates an upcoming New Drug Application (NDA) that could drive future revenue growth, enhancing market expectations for its valuation and potentially attracting more investor interest.
- Investment Case Analysis: Seeking Alpha's quantitative rating on Immunome reflects positive market sentiment, and combined with historical financial data, underscores the company's potential and investment value in the biopharmaceutical sector.
See More
Immunome Submits NDA for Varegacestat Supported by Positive Phase 3 RINGSIDE Results
- Clinical Trial Success: Immunome's Phase 3 RINGSIDE trial demonstrated a significant improvement in progression-free survival for varegacestat compared to placebo, with a hazard ratio of 0.16 (p<0.0001), providing robust data support for the New Drug Application and potentially transforming treatment options for adult patients.
- Significant Efficacy: The trial achieved a confirmed objective response rate of 56%, markedly higher than the 9% in the placebo group (p<0.0001), indicating that varegacestat has substantial clinical significance in treating progressing desmoid tumors, which may enhance patients' quality of life.
- Good Safety Profile: Although 82% of participants experienced adverse events like diarrhea, most were grade 1 or 2, indicating that varegacestat has a favorable safety and tolerability profile, making it an attractive treatment option.
- Future Outlook: Immunome plans to present detailed RINGSIDE data at the 2026 ASCO Annual Meeting, which could further elevate market interest in varegacestat and potentially drive its application in cancer treatment.
See More
Immunome CSO Sells Shares Under 10b5-1 Plan
- Transaction Overview: Immunome's Chief Scientific Officer Jack Higgins sold 9,438 shares of common stock on April 2, 2026, for a total value of $204,238.32, indicating a strategic approach to liquidity management.
- Ownership Changes: This sale reduced Higgins's direct holdings by 30.02%, from 31,438 to 22,000 shares, while his indirect holdings remained unchanged, reflecting his continued confidence in the company's future.
- Transaction Context: The sale was executed under a pre-arranged 10b5-1 trading plan established in December 2025, suggesting it was a routine liquidity management action rather than a market-timing decision, highlighting Higgins's financial diversification strategy.
- Company Outlook: Immunome is advancing its antibody therapeutic programs, particularly IMM-ONC-01 for cancer and IMM-BCP-01 for SARS-CoV-2, with a New Drug Application submission planned for Q2 2026, showcasing the company's strong growth potential in the biotechnology sector.
See More
Immunome's NDA for Varegacestat Accepted by FDA
- FDA Acceptance of NDA: Immunome's New Drug Application for varegacestat has been accepted by the FDA with a target action date of April 28, 2027, marking a significant milestone in providing a new oral treatment option for adults with desmoid tumors.
- Significant Clinical Trial Results: The Phase 3 RINGSIDE trial demonstrated that varegacestat met its primary endpoint by achieving an 84% reduction in the risk of disease progression or death, establishing a strong foundation for its market potential.
- Good Safety Profile: Varegacestat was generally well tolerated in the trial, with common adverse events such as diarrhea (82%) and fatigue (44%), and most events were grade 1 or 2, indicating an acceptable safety profile that supports future marketing efforts.
- Broad Market Potential: Approximately 1,000 to 1,650 patients are diagnosed with desmoid tumors annually in the U.S., and Immunome plans to submit a Marketing Authorization Application to the European Medicines Agency by the end of 2026, indicating its intent to expand in the global market.
See More
Immunome Receives FDA Acceptance for Varegacestat Application
- FDA Application Acceptance: Immunome announced that the U.S. FDA has accepted its marketing application for varegacestat, aimed at noncancerous soft tissue lesions, marking a significant advancement in the biotech sector.
- Clinical Trial Success: In the global Phase 3 RINGSIDE trial involving 156 patients, varegacestat achieved an 84% reduction in the risk of disease progression or death, demonstrating statistically significant clinical impact that could alter treatment paradigms.
- Secondary Goals Met: The RINGSIDE trial also met all key secondary endpoints, with an objective response rate of 56% in patients receiving varegacestat compared to just 9% in the placebo group, highlighting the drug's efficacy.
- Significant Market Potential: Approximately 1,000-1,650 Americans are diagnosed with desmoid tumors annually, requiring systemic treatment to prevent organ damage and pain, indicating a substantial market opportunity for this drug.
See More
Immunome Initiates Phase 1 Trial for IM-1617 ADC
- Trial Initiation: Immunome announced that the first patient has been dosed in the Phase 1 trial of IM-1617, an antibody-drug conjugate (ADC) aimed at assessing safety and preliminary anti-tumor activity, marking a significant advancement in targeted cancer therapies.
- Drug Mechanism: IM-1617 incorporates Immunome's proprietary topoisomerase I inhibitor HC74 and targets an undisclosed solid tumor receptor, with preclinical studies demonstrating impressive tumor regression across various models, indicating substantial clinical potential.
- Future Plans: Immunome plans to submit investigational new drug (IND) applications for IM-1340 and IM-1335 in mid and late 2026, respectively, reflecting the company's ongoing momentum and strategic focus in oncology drug development.
- Market Outlook: As IM-1617 progresses through clinical trials, Immunome anticipates strengthening its market position in targeted cancer therapies, providing innovative treatment options for patients and driving long-term growth for the company.
See More
Immunome Q1 Earnings Beat Expectations
- Earnings Surprise: Immunome reported a Q1 GAAP EPS of -$0.48, beating expectations by $0.09, indicating an improvement in financial performance that could bolster investor confidence.
- Strong Cash Position: As of March 31, 2026, Immunome's cash and cash equivalents totaled $582.7 million, which is expected to fund operations into 2028, ensuring continuity in research and operational activities.
- Optimistic Future Outlook: The company anticipates an upcoming New Drug Application (NDA) that could drive future revenue growth, enhancing market expectations for its valuation and potentially attracting more investor interest.
- Investment Case Analysis: Seeking Alpha's quantitative rating on Immunome reflects positive market sentiment, and combined with historical financial data, underscores the company's potential and investment value in the biopharmaceutical sector.
See More
Immunome Submits NDA for Varegacestat Supported by Positive Phase 3 RINGSIDE Results
- Clinical Trial Success: Immunome's Phase 3 RINGSIDE trial demonstrated a significant improvement in progression-free survival for varegacestat compared to placebo, with a hazard ratio of 0.16 (p<0.0001), providing robust data support for the New Drug Application and potentially transforming treatment options for adult patients.
- Significant Efficacy: The trial achieved a confirmed objective response rate of 56%, markedly higher than the 9% in the placebo group (p<0.0001), indicating that varegacestat has substantial clinical significance in treating progressing desmoid tumors, which may enhance patients' quality of life.
- Good Safety Profile: Although 82% of participants experienced adverse events like diarrhea, most were grade 1 or 2, indicating that varegacestat has a favorable safety and tolerability profile, making it an attractive treatment option.
- Future Outlook: Immunome plans to present detailed RINGSIDE data at the 2026 ASCO Annual Meeting, which could further elevate market interest in varegacestat and potentially drive its application in cancer treatment.
See More
Immunome CSO Sells Shares Under 10b5-1 Plan
- Transaction Overview: Immunome's Chief Scientific Officer Jack Higgins sold 9,438 shares of common stock on April 2, 2026, for a total value of $204,238.32, indicating a strategic approach to liquidity management.
- Ownership Changes: This sale reduced Higgins's direct holdings by 30.02%, from 31,438 to 22,000 shares, while his indirect holdings remained unchanged, reflecting his continued confidence in the company's future.
- Transaction Context: The sale was executed under a pre-arranged 10b5-1 trading plan established in December 2025, suggesting it was a routine liquidity management action rather than a market-timing decision, highlighting Higgins's financial diversification strategy.
- Company Outlook: Immunome is advancing its antibody therapeutic programs, particularly IMM-ONC-01 for cancer and IMM-BCP-01 for SARS-CoV-2, with a New Drug Application submission planned for Q2 2026, showcasing the company's strong growth potential in the biotechnology sector.
See More
